Brentuximab vedotin (replased/refractory Hodgkin lymphoma and CD30 positive non-Hodgkin lymphoma

Gan To Kagaku Ryoho. 2015 May;42(5):550-2.
No abstract available

MeSH terms

  • Brentuximab Vedotin
  • Hodgkin Disease / drug therapy*
  • Humans
  • Immunoconjugates / therapeutic use*
  • Ki-1 Antigen / immunology
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / immunology
  • Molecular Targeted Therapy
  • Recurrence

Substances

  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin